3.85

3.51% -0.14

X 4 Pharmaceuticals Inc (XFOR)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

X 4 Pharmaceuticals Inc stock is traded at $3.85, with a volume of 570.35K. It is down -3.51% in the last 24 hours and down -5.87% over the past month. X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Previous Close:

$3.99

Open:

24h Volume:

570.35K

Relative Volume:

0.90

Market Cap:

$363.13M

Revenue:

$9.01M

Net Income/Loss:

$-99.72M

P/E Ratio:

-0.8484

EPS:

-4.5381

Net Cash Flow:

$-92.85M

1W Performance:

+0.79%

1M Performance:

-5.87%

6M Performance:

+4.05%

1Y Performance:

+110.38%

1-Day Range:

$3.775

$4.00

1-Week Range:

$3.56

$4.01

52-Week Range:

$1.35

$4.83

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

Name

X 4 Pharmaceuticals Inc

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

857-529-8300

Address

61 NORTH BEACON STREET, BOSTON, MA

Employee

Twitter

@x4pharma

Next Earnings Date

2026-08-14

Latest SEC Filings

XFOR's Discussions on Twitter

Compare XFOR vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XFOR X 4 Pharmaceuticals Inc	3.85	363.13M	9.01M	-99.72M	-92.85M	-4.5381
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-09-26	Initiated	Guggenheim	Buy
Dec-05-25	Resumed	Stifel	Buy
Dec-12-23	Downgrade	B. Riley Securities	Buy → Neutral
Aug-30-23	Resumed	B. Riley Securities	Buy
Dec-22-22	Initiated	Cantor Fitzgerald	Overweight
Dec-12-22	Initiated	Piper Sandler	Overweight
Dec-23-19	Initiated	Oppenheimer	Outperform
Dec-18-19	Initiated	ROTH Capital	Buy
Dec-09-19	Upgrade	Citigroup	Neutral → Buy
Dec-05-19	Initiated	B. Riley FBR	Buy
Jun-07-19	Initiated	Stifel	Buy
Jun-05-19	Initiated	Cowen	Outperform

View All

X 4 Pharmaceuticals Inc Stock (XFOR) Latest News

Jul 25, 2026

XFOR|X4 Pharmaceuticals Inc|Price:3.850|Chg%:-0.140 - TradingKey

Jul 25, 2026

X4 Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:XFOR - TradingView

Jul 25, 2026

Jul 24, 2026

Form 4 Vertex Pharmaceuticals Inc For: 24 July By Investing.com - Investing.com South Africa

Jul 24, 2026

Jul 23, 2026

Layoff Tracker: CLINUVEL will cut up to 20% of staff, relocate HQ to New York - BioSpace

Jul 23, 2026

Jul 21, 2026

Form 4 Madrigal Pharmaceuticals Inc For: 21 July By Investing.com - Investing.com South Africa

Jul 21, 2026

Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy - Buffalo News

Jul 21, 2026

Jul 20, 2026

Frontier tech research, news & data - MLQ.ai

Jul 20, 2026

Jul 18, 2026